Interestingly, the binding site of silibinin to EGFR is different from that of oxitinib, one of the third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), suggesting that silibinin may also be effective on cancer cells harboring the EGFR mutant resistant to the EGFR-TKI [38]. Here, EGFR is linked to cancer.